Skip to main content
OpenTrials
Completed

NCT Number: NCT02439736

EVALUATION OF BIOMARKERS OF TRAUMATIC BRAIN INJURY EXTENSION STUDY

The primary objective of this study is to evaluate Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) biomarker levels in a population of CT-positive subjects (as determined by an independent Neuroimaging Review Committee) presenting acutely with traumatic brain injury (Glasgow Coma Scale score 9-15).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Klinikum rechts der Isar of the Technical University of Munich, Munich, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The Subject is at least 18 years of age at screening.
  • The Subject has presented to a Health Care Facility (HCF) or Emergency Department (ED) with a suspected traumatically induced head injury, as a result of insult to the head from an external force.
  • A Glasgow Coma Scale score of 9-15 at the time of Informed Consent.
  • The subject is CT-positive for acute intracranial lesion(s) based on the local neuroradiologist's review of the subject's head CT scan.
  • The CT scan and CT report used to determine eligibility must be available.
  • The blood sample is collected as close to the time of head injury as possible, but no later than 12 hours.
  • The Subject or their legal representative is willing to undergo the Informed Consent process prior to enrollment into this study

Exclusion criteria

  • Participating in an interventional, therapeutic clinical study that may affect the results of this study (an observational study would be acceptable).
  • Time of injury cannot be determined.
  • Primary diagnosis of ischemic or hemorrhagic stroke.
  • Venipuncture not feasible (i.e., skin integrity compromised at the venipuncture sites, blood vessel calcification (i.e., IV drug users, advanced atherosclerosis) both upper limbs missing (congenital or amputee)).
  • The subject has a neurodegenerative disease or other neurological disorder including dementia, Parkinson's disease, multiple sclerosis, seizure disorder, or brain tumors.
  • The subject has a history of neurosurgery within the last 30 days.
  • Administration of blood transfusion after head injury and prior to the study blood draw.
  • The subject is a female who is pregnant or lactating.
  • The Subject is otherwise determined by the Investigator to be an unsuitable candidate for participation. If this criterion applies, a reason must be provided

Treatment and study plan

Blood draw within 12 hours of head injury

Other

Primary outcomes

  1. Correlation of assay results with presence of acute intracranial lesions

    Time frame: Day 1

Sponsors and collaborators

Lead sponsor

Banyan Biomarkers, Inc

Industry

Collaborators

  • U.S. Army Medical Research and Development Command

Registry information

Official study title

A PROSPECTIVE CLINICAL EVALUATION OF BIOMARKERS OF TRAUMATIC BRAIN INJURY EXTENSION STUDY

Acronym: ALERT-TBIx

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
May 12, 2015
Registry last updated
Aug 8, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.